Abbott Laboratories: Cardiovascular Disease Has Been A Tailwind, But Things Could Change [Seeking Alpha]
Abbott Laboratories (ABT)
Last abbott laboratories earnings: 4/16 07:30 am
Check Earnings Report
US:NYSE Investor Relations:
abbott.com/investors.html
Company Research
Source: Seeking Alpha
Summary Cardiovascular disease is rising, presenting an opportunity for investors; Abbott Laboratories is well-positioned in the CVD treatment space to benefit from this trend. Abbott's recent double-digit growth in medical devices, particularly in its CVD segment, underscores its strong market position and potential for continued success. Abbott's focus on glucose monitoring aligns with the link between sugar levels and CVD, further strengthening its growth prospects in this critical area. Despite a seemingly high valuation, Abbott's growth potential and resilience in a potential recession make it an attractive investment option for both growth and stability. Investors need to consider the possibility that CVD may revert back to the downward trend pre-pandemic. Eoneren Preamble This article is a positive one for Abbott Laboratories NYSE: ABT ) investors for lamentable circumstances. It would appear that cardiovascular disease, already one of the most common causes of
Show less
Read more
Impact Snapshot
Event Time:
ABT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABT alerts
High impacting Abbott Laboratories news events
Weekly update
A roundup of the hottest topics
ABT
News
- WHO approves Abbott's mpox test for emergency use [Yahoo! Finance]Yahoo! Finance
- $19.3 Bn Clinical Chemistry Analyzers Industry Overview 2024 and Forecasts to 2030 [Yahoo! Finance]Yahoo! Finance
- WHO approves first mpox diagnostic test for emergency use [Seeking Alpha]Seeking Alpha
- Enzyme-Linked Immunosorbent Assay (ELISA) Market to Grow by USD 843.9 Million (2024-2028) as AI Drives Demand for Frequent Diagnostic Testing [Yahoo! Finance]Yahoo! Finance
- WHO approves first mpox diagnostic test for emergency use [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
ABT
Earnings
- 7/18/24 - Beat
ABT
Sec Filings
- 10/1/24 - Form 4
- 10/1/24 - Form 4
- 10/1/24 - Form 4
- ABT's page on the SEC website